1. Silymarin: a review of its clincal properties in the managment of hepatic disorders
Keri et al.
Adis Drug Evaluation, Biodrugs 2001: 15 (7): 465-489
2. Use of herbal supplements for chronic liver disease.
Cynthia Levy et al.
Clin. Gast. And Hepat. 2004;2:947-956
3. Updated medicines and the liver.
Fogden E et al.
Liver International 2003, 23, 213-220
4. An updated systemic review of the pharmacology of silymarin
Reinhard Saller et al.
Forsch Komplementarmed 2007;14:70-80
5. Self-emulsifying drug delivery systems: Strategy for improving oral delivery of poorly soluble drugs.
Jing-ling et al.
Current Drug Therapy, 2007 Vol. 2, No. 1
6. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system.
Wei Wu et al.
European Journal of Pharmaceuticals and Biopharm. 63(3) (2006) 288-294
7. Formulation and biopharmaceutical evaluation of silymarin of SMEDDS
Woo et al.
Arch Pharm Res Vol 30, No 1, 82-89, 2007
8. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction.
Schandalik R. et al.
Drugs Exp Clin Res. 1994;20(1):37-42.
9. Pharmacokinetic studies with silymarin in human serum and bile.
Lorenz D, et al.
Methods Find Exp Clin Pharmacol. 1984 Oct;6(10):655-61.
10. The solubility and bioequivalence of silymarin preparations
Schulz HU, et al
Arzneimittelforschung. 1995 Jan;45(1):61-4.
11. [Preparation of silybin-phospholipid complex and its bioavailability in rats][Article in Chinese]
Xiao YY, et al.
Yao Xue Xue Bao. 2005 Jul;40(7):611-7.
12. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos).
Kidd P, et al.
Altern Med Rev. 2005 Sep;10(3):193-203.
13. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi N, et al.
Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):333-8.
14. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches.
Nitin Dixit et al.
Indian J Pharmacol. 2007, Vol. 3 Issue 4, 172-179
15. Anabolic steroids and cholestasis
Nusinovici V.
Med Chir Dig. 1974;3(3):167-71.
16. Cholestasis due to anabolic steroids
Horký J, et al.
Cesk Gastroenterol Vyz. 1973 Dec;27(8):548-50.
17. Drug-induced cholestasis.
Velayudham LS, et al.
Expert Opin Drug Saf. 2003 May;2(3):287-304.
18. Beneficial drugs for liver diseases.
Muriel P, et al.
J Appl Toxicol. 2008 Mar;28(2):93-103. Review.
19. Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication.
Crocenzi FA, Roma MG.
Curr Med Chem. 2006;13(9):1055-74. Review.
20. Silibinin prevents cholestasis-associated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: possible involvement of cAMP.
Crocenzi FA, et al.
Biochem Pharmacol. 2005 Apr 1;69(7):1113-20.
21. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets.
Crocenzi FA, et al.
Hepatology. 2001 Aug;34(2):329-39.
22. Tauro alpha-muricholate is as effective as tauro beta-muricholate and tauroursodeoxycholate in preventing taurochenodeoxycholate-induced liver damage in the rat.
Kitani K, et al.
Hepatology. 1994 Apr;19(4):1007-12.
23. Tauro beta-muricholate is as effective as tauroursodeoxycholate in preventing taurochenodeoxycholate-induced liver damage in the rat.
Kanai S, et al.
Life Sci. 1990;47(26):2421-8.
24. Cholestatic Jaundice and IgA Nephropathy Induced by OTC Muscle Building Agent Superdrol.
Beata Jasiurkowski MD, et al.
The American Journal of Gastroenterology (2006) 101, 2659-2662;
25. Severe Cholestasis and Renal Failure Associated with the Use of the Designer Steroid Superdrol (Methasteron): A Case Report and Literature Review
John Nasr and Jawad Ahmad
Digestive Diseases and Sciences
26. Improvement of estradiol-17b-d-glucoronide-induced cholestasis by sodium tauroursodeoxycholate therapy in rats.
Kinbara S et al.
Pharm. Research Laboratory, 1997, 947-952
27. Ursodeoxycholate reduces ethinylestradiol glucuronidation in the rat: Role in prevention of estrogen-induced cholestasis.
Enrique J et al.
The Journal of Pharmacology and experimental therapeutics, 2003 Vol. 306, No. 1 279-286
28. Hepatoprotective effects of silymarin in androgenic-anabolic steroid-induced liver damage
Radovanovi D et al.
Med Pregl. 2003;56 Suppl 1:79-83.
29. Milk thistle (silybum marianum) for the therapy of liver disease
Kenneth Flora et al.
The American Journal of Gastroenterology. Vol. 93, No. 2, 1998